Literature DB >> 18251694

Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.

Laura M Zarebski1, Kerrie Vaughan, John Sidney, Bjoern Peters, Howard Grey, Kim D Janda, Arturo Casadevall, Alessandro Sette.   

Abstract

We have reviewed the information about epitopes of immunological interest from Clostridium botulinum and Bacillus anthracis, by mining the Immune Epitope Database and Analysis Resource. For both pathogens, the vast majority of epitopes reported to date are derived from a single protein: the protective antigen of B. anthracis and the neurotoxin type A of C. botulinum. A detailed analysis of the data was performed to characterize the function, localization and conservancy of epitopes identified as neutralizing and/or protective. In order to broaden the scope of this analysis, we have also included data describing immune responses against defined fragments (over 50 amino acids long) of the relevant antigens. The scarce information on T-cell determinants and on epitopes from other antigens besides the toxins, highlights a gap in our knowledge and identifies areas for future research. Despite this, several distinct structures at the epitope and fragment level are described herein, which could be potential additions to future vaccines or targets of novel immunotherapeutics and diagnostic reagents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251694      PMCID: PMC3319117          DOI: 10.1586/14760584.7.1.55

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  98 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases.

Authors:  S Goyard; C Orlando; J M Sabatier; E Labruyere; J d'Alayer; G Fontan; J van Rietschoten; M Mock; A Danchin; A Ullmann
Journal:  Biochemistry       Date:  1989-03-07       Impact factor: 3.162

4.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Authors:  M Z Atassi; B Z Dolimbek; M Hayakari; J L Middlebrook; B Whitney; M Oshima
Journal:  J Protein Chem       Date:  1996-10

7.  Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.

Authors:  S A Ahmed; L A Smith
Journal:  J Protein Chem       Date:  2000-08

8.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

9.  The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria.

Authors:  Timothy D Read; Scott N Peterson; Nicolas Tourasse; Les W Baillie; Ian T Paulsen; Karen E Nelson; Hervé Tettelin; Derrick E Fouts; Jonathan A Eisen; Steven R Gill; Erik K Holtzapple; Ole Andreas Okstad; Erlendur Helgason; Jennifer Rilstone; Martin Wu; James F Kolonay; Maureen J Beanan; Robert J Dodson; Lauren M Brinkac; Michelle Gwinn; Robert T DeBoy; Ramana Madpu; Sean C Daugherty; A Scott Durkin; Daniel H Haft; William C Nelson; Jeremy D Peterson; Mihai Pop; Hoda M Khouri; Diana Radune; Jonathan L Benton; Yasmin Mahamoud; Lingxia Jiang; Ioana R Hance; Janice F Weidman; Kristi J Berry; Roger D Plaut; Alex M Wolf; Kisha L Watkins; William C Nierman; Alyson Hazen; Robin Cline; Caroline Redmond; Joanne E Thwaite; Owen White; Steven L Salzberg; Brendan Thomason; Arthur M Friedlander; Theresa M Koehler; Philip C Hanna; Anne-Brit Kolstø; Claire M Fraser
Journal:  Nature       Date:  2003-05-01       Impact factor: 49.962

10.  Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Michael J Gubbins; Jody D Berry; Cindi R Corbett; Jeremy Mogridge; Xin Y Yuan; Lisa Schmidt; Brigitte Nicolas; Amin Kabani; Raymond S Tsang
Journal:  FEMS Immunol Med Microbiol       Date:  2006-08
View more
  19 in total

1.  NIAID workshop on Flavivirus immunity.

Authors:  Alison D Augustine; M Cristina Cassetti; Francis A Ennis; Eva Harris; William H Hildebrand; Patricia M Repik
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

2.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

3.  Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222.

Authors:  Mark J Jacobson; Guangyun Lin; William Tepp; Jerome Dupuy; Pål Stenmark; Raymond C Stevens; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2011-04-22       Impact factor: 4.792

4.  A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.

Authors:  Adva Mechaly; Haim Levy; Eyal Epstein; Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Avigdor Shafferman; Arie Ordentlich; Ohad Mazor
Journal:  J Biol Chem       Date:  2012-08-06       Impact factor: 5.157

5.  Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production.

Authors:  Carla Oseroff; John Sidney; Victoria Tripple; Howard Grey; Robert Wood; David H Broide; Jason Greenbaum; Ravi Kolla; Bjoern Peters; Anna Pomés; Alessandro Sette
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

6.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues.

Authors:  K Vaughan; M Blythe; J Greenbaum; Q Zhang; B Peters; D L Doolan; A Sette
Journal:  Parasite Immunol       Date:  2009-02       Impact factor: 2.280

Review 8.  Design and utilization of epitope-based databases and predictive tools.

Authors:  Nima Salimi; Ward Fleri; Bjoern Peters; Alessandro Sette
Journal:  Immunogenetics       Date:  2010-03-06       Impact factor: 2.846

9.  Recent advances in B-cell epitope prediction methods.

Authors:  Yasser El-Manzalawy; Vasant Honavar
Journal:  Immunome Res       Date:  2010-11-03

10.  Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Authors:  Cassandra D Kelly-Cirino; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.